Prognosis of Pregnancy-Associated Gastric Cancer: An Age-, Sex-, and Stage-Matched Case-Control Study
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: Pregnancy-associated gastric cancer is a rare condition. This case-control study was performed to identify the clinicopathological features and prognostic factors of pregnancy-associated gastric cancer. Methods: All consecutive patients who presented to our tertiary referral hospital with pregnancy-associated gastric cancer from 1991 to 2012 were identified. Two age-, sex-, and stagematched controls for each case were also identified from the records. Clinicopathological, gynecological, and oncological outcomes were recorded. Immunohistochemical staining was performed for estrogen receptor, progesterone receptor, epidermal growth factor receptor, human epidermal growth factor receptor, and E-cadherin. Fluorescence in situ hybridization was performed for fibroblast growth factor receptor 2. Results: The median overall survival rates of the pregnancyassociated gastric cancer and control groups were 7.0 months and 15.0 months, respectively (p=0.189). Poor prognostic factors included advanced stage and tumor location in the corpus or the entire stomach but not pregnancy status or loss of E-cadherin. Pregnancy-associated gastric cancer was associated with a longer time from diagnosis to treatment (21 days vs 7 days, p=0.021). The two groups did not differ in the expression of the receptors or E-cadherin. Conclusions: The dismal prognosis of pregnancy-associated gastric cancer may related to the tumor stage and location rather than to pregnancy itself.
Abstract
Background/Aims: Pregnancy-associated gastric cancer is a rare condition. This case-control study was performed to identify the clinicopathological features and prognostic factors of pregnancy-associated gastric cancer. Methods: All consecutive patients who presented to our tertiary referral hospital with pregnancy-associated gastric cancer from 1991 to 2012 were identified. Two age-, sex-, and stagematched controls for each case were also identified from the records. Clinicopathological, gynecological, and oncological outcomes were recorded. Immunohistochemical staining was performed for estrogen receptor, progesterone receptor, epidermal growth factor receptor, human epidermal growth factor receptor, and E-cadherin. Fluorescence in situ hybridization was performed for fibroblast growth factor receptor 2. Results: The median overall survival rates of the pregnancyassociated gastric cancer and control groups were 7.0 months and 15.0 months, respectively (p=0.189). Poor prognostic factors included advanced stage and tumor location in the corpus or the entire stomach but not pregnancy status or loss of E-cadherin. Pregnancy-associated gastric cancer was associated with a longer time from diagnosis to treatment (21 days vs 7 days, p=0.021). The two groups did not differ in the expression of the receptors or E-cadherin. Conclusions: The dismal prognosis of pregnancy-associated gastric cancer may related to the tumor stage and location rather than to pregnancy itself.
참고문헌 (27)
- Crew KD, "Epidemiology of gastric cancer", World J Gastroenterol, 12, pp.354~362 (2006)
- Jemal A, "Cancer statistics, 2006", CA Cancer J Clin, 56, pp.106~130 (2006)
- Al-Refaie WB, "Gastric adenocarcinoma in young patients: a population-based appraisal", Ann Surg Oncol, 18, pp.2800~2807 (2011)
- Sakamoto K, "Management of patients with pregnancy-associated gastric cancer in Japan: a mini-review", Int J Clin Oncol, 14, pp.392~396 (2009)
- Ueo H, "Prognosis in gastric cancer associated with pregnancy", World J Surg, 15, pp.293~297 (1991)
- Kodama I, "Gastric cancer during pregnancy", Kurume Med J, 44, pp.179~183 (1997)
- Lee HJ, "Clinical characteristics of gastric cancer associated with pregnancy", Dig Surg, 26, pp.31~36 (2009)
- Suh M, "Cancer screening in Korea, 2012: results from the Korean National Cancer Screening Survey", Asian Pac J Cancer Prev, 14, pp.6459~6463 (2013)
- Lai JF, "Clinicopathologic characteristics and prognosis for young gastric adenocarcinoma patients after curative resection", Ann Surg Oncol, 15, pp.1464~1469 (2008)
- Saito H, "Clinicopathologic characteristics and prognosis of gastric cancer in young patients", Yonago Acta Med, 55, pp.57~61 (2012)
- Isobe T, "Characteristics and prognosis of gastric cancer in young patients", Oncol Rep, 30, pp.43~49 (2013)
- Tavares A, "Analysis of clinicopathologic characteristics and prognosis of gastric cancer in young and older patients", Pathol Oncol Res, 19, pp.111~117 (2013)
- Santoro R, "Clinicopathological features and prognosis of gastric cancer in young European adults", Br J Surg, 94, pp.737~742 (2007)
- Park HJ, "Clinical characteristics and outcomes for gastric cancer patients aged 18-30 years", Gastric Cancer, 17, pp.649~660 (2014)
- Milne AN, "Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers", Mod Pathol, 19, pp.564~572 (2006)
- Harrison JD, "The effect of sex hormones and tamoxifen on the growth of human gastric and colorectal cancer cell lines", Cancer, 63, pp.2148~2151 (1989)
- Jaspers VK, "Gastric cancer in pregnancy:do pregnancy, age or female sex alter the prognosis? Case reports and review", Eur J Obstet Gynecol Reprod Biol, 87, pp.13~22 (1999)
- Palli D, "Reproductive history and gastric cancer among post-menopausal women", Int J Cancer, 56, pp.812~815 (1994)
- Oh HS, "Prognostic implications of EGFR and HER-2 alteration assessed by immunohistochemistry and silver in situ hybridization in gastric cancer patients following curative resection", Gastric Cancer, 17, pp.402~411 (2014)
- Moelans CB, "Low frequency of HER2 amplification and overexpression in early onset gastric cancer", Cell Oncol, 34, pp.89~95 (2011)
- Kim YH, "Randomized phase II study of nimotuzumab, an anti-EGFR antibody, plus irinotecan in patients with 5-fluorouracil-based regimen-refractory advanced or recurrent gastric cancer in Korea and Japan: preliminary results", J Clin Oncol, 29(4), pp.87~ (2011)
- Bang YJ, "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial", Lancet, 376, pp.687~697 (2010)
- Matsumoto K, "FGFR2 gene amplification and clinicopathological features in gastric cancer", Br J Cancer, 106, pp.727~732 (2012)
- Toyokawa T, "Co-expression of keratinocyte growth factor and K-sam is an independent prognostic factor in gastric carcinoma", Oncol Rep, 21, pp.875~880 (2009)
- Suriano G, "Identification of CDH1germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands", Hum Mol Genet, 12, pp.575~582 (2003)
- Kokkola A, "Gastric carcinoma in young adults", Hepatogastroenterology, 48, pp.1552~1555 (2001)
- Corso G, "Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer", J Clin Oncol, 31, pp.868~875 (2013)